$1.27
-0.01 (-0.78%)
Open$1.27
Previous Close$1.28
Day High$1.29
Day Low$1.24
52W High$24.50
52W Low$0.96
Volume—
Avg Volume896.7K
Market Cap6.77M
P/E Ratio—
EPS$-21.69
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,212.6% upside
Current
$1.27
$1.27
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.33M | 586.6K | 551.3K |
| Net Income | -114,922,915 | -23,280 | -22,798 |
| Profit Margin | -862.3% | -4.0% | -4.1% |
| EBITDA | -115,487,895 | -32,929 | -31,435 |
| Free Cash Flow | — | -20,426 | -16,844 |
| Rev Growth | +212.6% | +23.9% | +11.9% |
| Debt/Equity | — | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |